Amphastar Pharmaceuticals, Inc. AMPH
We take great care to ensure that the data presented and summarized in this overview for Amphastar Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMPH
View all-
Black Rock Inc. New York, NY5.94MShares$262 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.71MShares$120 Million0.0% of portfolio
-
Td Asset Management Inc2.14MShares$94.1 Million0.1% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA1.95MShares$85.8 Million0.22% of portfolio
-
Neuberger Berman Group LLC New York, NY1.62MShares$71.2 Million0.06% of portfolio
-
State Street Corp Boston, MA1.53MShares$67.5 Million0.0% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.26MShares$55.6 Million0.24% of portfolio
-
Epoch Investment Partners, Inc. New York, NY1.19MShares$52.5 Million0.27% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.09MShares$48.2 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA920KShares$40.6 Million0.0% of portfolio
Latest Institutional Activity in AMPH
Top Purchases
Top Sells
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Insider Transactions at AMPH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 12
2024
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
SELL
Open market or private sale
|
Direct |
6,893
-5.5%
|
$330,864
$48.88 P/Share
|
Nov 12
2024
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,893
+5.22%
|
$96,502
$14.95 P/Share
|
Nov 12
2024
|
Richard K Prins |
SELL
Bona fide gift
|
Direct |
1,000
-3.18%
|
-
|
Nov 12
2024
|
Richard K Prins |
SELL
Open market or private sale
|
Direct |
5,000
-13.71%
|
$240,000
$48.8 P/Share
|
Nov 12
2024
|
Richard K Prins |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+6.42%
|
$40,000
$16.69 P/Share
|
Nov 11
2024
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Bona fide gift
|
Indirect |
125,000
-10.16%
|
-
|
Nov 11
2024
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
SELL
Bona fide gift
|
Direct |
125,000
-4.75%
|
-
|
Nov 06
2024
|
Yakob Liawatidewi EVP CORP ADMIN CENTER |
SELL
Open market or private sale
|
Direct |
5,214
-6.51%
|
$271,128
$52.05 P/Share
|
Nov 06
2024
|
Yakob Liawatidewi EVP CORP ADMIN CENTER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,214
+6.11%
|
$67,782
$13.03 P/Share
|
Nov 06
2024
|
William J Peters CFO, EVP & TREASURER |
SELL
Open market or private sale
|
Direct |
7,426
-7.31%
|
$386,152
$52.05 P/Share
|
Nov 06
2024
|
William J Peters CFO, EVP & TREASURER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,426
+6.82%
|
$96,538
$13.03 P/Share
|
Sep 13
2024
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
SELL
Open market or private sale
|
Direct |
3,000
-2.47%
|
$144,000
$48.26 P/Share
|
Sep 13
2024
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.41%
|
$42,000
$14.95 P/Share
|
Sep 13
2024
|
Jack Y. Zhang CEO & CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+3.66%
|
$1,400,000
$14.69 P/Share
|
Sep 05
2024
|
Floyd F. Petersen |
SELL
Open market or private sale
|
Direct |
3,000
-3.83%
|
$138,000
$46.47 P/Share
|
Aug 26
2024
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
SELL
Open market or private sale
|
Direct |
4,000
-3.27%
|
$192,000
$48.35 P/Share
|
Aug 26
2024
|
Rong Zhou SENIOR EVP, PRODUCTION CENTER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+3.16%
|
$56,000
$14.95 P/Share
|
Aug 12
2024
|
Richard K Prins |
SELL
Open market or private sale
|
Direct |
17,101
-33.48%
|
$735,343
$43.07 P/Share
|
Aug 12
2024
|
Richard K Prins |
BUY
Exercise of conversion of derivative security
|
Direct |
17,101
+11.24%
|
$324,919
$19.88 P/Share
|
Jul 31
2024
|
William J Peters CFO, EVP & TREASURER |
SELL
Open market or private sale
|
Direct |
10,282
-9.85%
|
$452,408
$44.23 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 153K shares |
---|---|
Exercise of conversion of derivative security | 1.31M shares |
Open market or private sale | 466K shares |
---|---|
Payment of exercise price or tax liability | 672K shares |
Bona fide gift | 252K shares |